TY - JOUR
T1 - Body-mass index and all-cause mortality
T2 - individual-participant-data meta-analysis of 239 prospective studies in four continents
AU - Di Angelantonio, Emanuele
AU - Bhupathiraju, Shilpa N.
AU - Wormser, David
AU - Gao, Pei
AU - Kaptoge, Stephen
AU - de Gonzalez, Amy Berrington
AU - Cairns, Benjamin J.
AU - Huxley, Rachel
AU - Jackson, Chandra L.
AU - Joshy, Grace
AU - Lewington, Sarah
AU - Manson, Jo Ann E.
AU - Murphy, Neil
AU - Patel, Alpa V.
AU - Samet, Jonathan M.
AU - Woodward, Mark
AU - Zheng, Wei
AU - Zhou, Maigen
AU - Bansal, Narinder
AU - Barricarte, Aurelio
AU - Carter, Brian
AU - Cerhan, James R.
AU - Collins, Rory
AU - Smith, George Davey
AU - Fang, Xianghua
AU - Franco, Oscar H.
AU - Green, Jane
AU - Halsey, Jim
AU - Hildebrand, Janet S.
AU - Ji Jung, Keum
AU - Korda, Rosemary J.
AU - McLerran, Dale F.
AU - Moore, Steven C.
AU - O'Keeffe, Linda M.
AU - Paige, Ellie
AU - Ramond, Anna
AU - Reeves, Gillian K.
AU - Rolland, Betsy
AU - Sacerdote, Carlotta
AU - Sattar, Naveed
AU - Anopoulou, Eleni Sofi
AU - Stevens, June
AU - Thun, Michael
AU - Ueshima, Hirotsugu
AU - Yang, Ling
AU - Duk Yun, Young
AU - Willeit, Peter
AU - Banks, Emily
AU - Beral, Valerie
AU - Chen, Zhengming
AU - Gapstur, Susan M.
AU - Gunter, Marc J.
AU - Hartge, Patricia
AU - Jee, Sun Ha
AU - Lam, Tai Hing
AU - Peto, Richard
AU - Potter, John D.
AU - Willett, Walter C.
AU - Thompson, Simon G.
AU - Danesh, John
AU - Hu, Frank B.
N1 - Funding Information:
EDA received research funding from UK Medical Research Council, British Heart Foundation, National Institute of Health Research, NHS Blood and Transplant, European Commission Framework Programme during the conduct of the study; and personal fees from Elsevier (France). Since January, 2014, DW has been a full-time employee of F. Hoffmann-La Roche and received personal fees and holding shares in F. Hoffmann-La Roche. PG received grants from Recruitment Program for Young Professionals in China and British Heart Foundation. BJC, JG, GKR, and VB received research funding from Cancer Research UK and Medical Research Council. BJC received funding from the British Heart Foundation Centre of Research Excellence, Oxford. MW received personal fees from Novartis and Amgen. OHF received research funding from Nestle and Metagenics. RJK received grants from National Health and Medical Research Council. NS received personal fees from AstraZeneca, Boehringer Ingelheim, and Janssen. EB received grants from National Health and Medical Research Council of Australia and National Heart Foundation of Australia. SGT received grants from UK Medical Research Council and British Heart Foundation. JD has received research funding from the British Heart Foundation, NIHR Cambridge Comprehensive Biomedical Research Centre, BUPA Foundation, diaDexus, European Research Council, European Union, Evelyn Trust, Fogarty International Centre, GlaxoSmithKline, Merck, National Heart, Lung and Blood Institute, National Institute for Health Research, National Institute of Neurological Disorders and Stroke, NHS Blood and Transplant, Novartis, Pfizer, UK Medical Research Council, and Wellcome Trust. All other members of the writing committee declare no competing interests.
Funding Information:
This paper is dedicated to the memory of Gary Whitlock , who contributed much to developing the collaboration. Global BMI Mortality Collaboration provides links to websites of the component studies (or consortia), many of which describe their funding. The coordinating centre at the University of Cambridge was funded by the UK Medical Research Council (G0800270), British Heart Foundation (SP/09/002), British Heart Foundation Cambridge Cardiovascular Centre of Excellence, and National Institute for Health Research Cambridge Biomedical Research Centre. The work of the coordinating centre at the Harvard TH Chan School of Public Health was funded by grants P01 CA87969, UM1 CA176726, UM1 CA167552, DK58845, P30 DK046200, and U54 CA155626 from the National Institutes of Health. This research has been conducted using the UK Biobank resource.
Publisher Copyright:
© 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC-BY license
PY - 2016/8/20
Y1 - 2016/8/20
N2 - Background Overweight and obesity are increasing worldwide. To help assess their relevance to mortality in different populations we conducted individual-participant data meta-analyses of prospective studies of body-mass index (BMI), limiting confounding and reverse causality by restricting analyses to never-smokers and excluding pre-existing disease and the first 5 years of follow-up. Methods Of 10 625 411 participants in Asia, Australia and New Zealand, Europe, and North America from 239 prospective studies (median follow-up 13·7 years, IQR 11·4–14·7), 3 951 455 people in 189 studies were never-smokers without chronic diseases at recruitment who survived 5 years, of whom 385 879 died. The primary analyses are of these deaths, and study, age, and sex adjusted hazard ratios (HRs), relative to BMI 22·5–<25·0 kg/m2. Findings All-cause mortality was minimal at 20·0–25·0 kg/m2 (HR 1·00, 95% CI 0·98–1·02 for BMI 20·0–<22·5 kg/m2; 1·00, 0·99–1·01 for BMI 22·5–<25·0 kg/m2), and increased significantly both just below this range (1·13, 1·09–1·17 for BMI 18·5–<20·0 kg/m2; 1·51, 1·43–1·59 for BMI 15·0–<18·5) and throughout the overweight range (1·07, 1·07–1·08 for BMI 25·0–<27·5 kg/m2; 1·20, 1·18–1·22 for BMI 27·5–<30·0 kg/m2). The HR for obesity grade 1 (BMI 30·0–<35·0 kg/m2) was 1·45, 95% CI 1·41–1·48; the HR for obesity grade 2 (35·0–<40·0 kg/m2) was 1·94, 1·87–2·01; and the HR for obesity grade 3 (40·0–<60·0 kg/m2) was 2·76, 2·60–2·92. For BMI over 25·0 kg/m2, mortality increased approximately log-linearly with BMI; the HR per 5 kg/m2 units higher BMI was 1·39 (1·34–1·43) in Europe, 1·29 (1·26–1·32) in North America, 1·39 (1·34–1·44) in east Asia, and 1·31 (1·27–1·35) in Australia and New Zealand. This HR per 5 kg/m2 units higher BMI (for BMI over 25 kg/m2) was greater in younger than older people (1·52, 95% CI 1·47–1·56, for BMI measured at 35–49 years vs 1·21, 1·17–1·25, for BMI measured at 70–89 years; pheterogeneity<0·0001), greater in men than women (1·51, 1·46–1·56, vs 1·30, 1·26–1·33; pheterogeneity<0·0001), but similar in studies with self-reported and measured BMI. Interpretation The associations of both overweight and obesity with higher all-cause mortality were broadly consistent in four continents. This finding supports strategies to combat the entire spectrum of excess adiposity in many populations. Funding UK Medical Research Council, British Heart Foundation, National Institute for Health Research, US National Institutes of Health.
AB - Background Overweight and obesity are increasing worldwide. To help assess their relevance to mortality in different populations we conducted individual-participant data meta-analyses of prospective studies of body-mass index (BMI), limiting confounding and reverse causality by restricting analyses to never-smokers and excluding pre-existing disease and the first 5 years of follow-up. Methods Of 10 625 411 participants in Asia, Australia and New Zealand, Europe, and North America from 239 prospective studies (median follow-up 13·7 years, IQR 11·4–14·7), 3 951 455 people in 189 studies were never-smokers without chronic diseases at recruitment who survived 5 years, of whom 385 879 died. The primary analyses are of these deaths, and study, age, and sex adjusted hazard ratios (HRs), relative to BMI 22·5–<25·0 kg/m2. Findings All-cause mortality was minimal at 20·0–25·0 kg/m2 (HR 1·00, 95% CI 0·98–1·02 for BMI 20·0–<22·5 kg/m2; 1·00, 0·99–1·01 for BMI 22·5–<25·0 kg/m2), and increased significantly both just below this range (1·13, 1·09–1·17 for BMI 18·5–<20·0 kg/m2; 1·51, 1·43–1·59 for BMI 15·0–<18·5) and throughout the overweight range (1·07, 1·07–1·08 for BMI 25·0–<27·5 kg/m2; 1·20, 1·18–1·22 for BMI 27·5–<30·0 kg/m2). The HR for obesity grade 1 (BMI 30·0–<35·0 kg/m2) was 1·45, 95% CI 1·41–1·48; the HR for obesity grade 2 (35·0–<40·0 kg/m2) was 1·94, 1·87–2·01; and the HR for obesity grade 3 (40·0–<60·0 kg/m2) was 2·76, 2·60–2·92. For BMI over 25·0 kg/m2, mortality increased approximately log-linearly with BMI; the HR per 5 kg/m2 units higher BMI was 1·39 (1·34–1·43) in Europe, 1·29 (1·26–1·32) in North America, 1·39 (1·34–1·44) in east Asia, and 1·31 (1·27–1·35) in Australia and New Zealand. This HR per 5 kg/m2 units higher BMI (for BMI over 25 kg/m2) was greater in younger than older people (1·52, 95% CI 1·47–1·56, for BMI measured at 35–49 years vs 1·21, 1·17–1·25, for BMI measured at 70–89 years; pheterogeneity<0·0001), greater in men than women (1·51, 1·46–1·56, vs 1·30, 1·26–1·33; pheterogeneity<0·0001), but similar in studies with self-reported and measured BMI. Interpretation The associations of both overweight and obesity with higher all-cause mortality were broadly consistent in four continents. This finding supports strategies to combat the entire spectrum of excess adiposity in many populations. Funding UK Medical Research Council, British Heart Foundation, National Institute for Health Research, US National Institutes of Health.
UR - http://www.scopus.com/inward/record.url?scp=84978919932&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978919932&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(16)30175-1
DO - 10.1016/S0140-6736(16)30175-1
M3 - Article
C2 - 27423262
AN - SCOPUS:84978919932
VL - 388
SP - 776
EP - 786
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 10046
ER -